Frontier mental health research: psychedelics & drug studies

Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.

1 paper

Ayahuasca for Addiction

Based on 11 papers

Research on ayahuasca for addiction is small but growing. Reviews and lab studies say the brew’s main ingredient (DMT) acts on brain serotonin systems and can boost the brain’s ability to rewire itself. This gives a scientific reason why ayahuasca might help people change long‑standing habits, but clinical trials specifically testing ayahuasca for addiction are limited and early. People who study psychedelic therapies agree that the drug itself is only part of the story. How a person is prepared, the setting, and follow‑up therapy matter a lot. There are also safety and fairness concerns. Some related drugs (like ibogaine) showed help for addiction but also caused serious heart and brain risks. Many studies are small, and people of color were often left out, so we cannot be sure the results apply to everyone.

Key findings

  • Some reviews say psychedelics, including DMT in ayahuasca, show promise for treating substance use problems, but the evidence is still early and not definitive. 15059 15058 15082
  • Ayahuasca’s active chemical, DMT, mainly affects serotonin receptors and lab studies show it can help the brain form new connections (called neuroplasticity). This may be one reason it could help break old habits. 15082 15050 15091
  • Clinical research specifically testing ayahuasca for addiction is limited. Most larger or later‑stage trials so far focus on other psychedelics like psilocybin or MDMA, not ayahuasca. 15082 15063 15085
  • People who have had psychedelic treatments often report deep personal insights, a changed sense of self, and stronger social connection. These kinds of changes are commonly described in studies and may relate to recovery from addiction. 15092 15059 15063
  • Non‑drug factors—such as preparation, the therapy during and after the session, the relationship with the therapist, and the setting—strongly shape outcomes. That means benefits seen in studies may depend on more than the brew itself. 15092 15063 15087
  • Some related plant medicines show both promise and real risks. For example, ibogaine has shown signs of helping addiction in some studies but has caused serious cardiac and neurological problems in other cases. 15085
  • Overall evidence strength is limited. Many studies are small, early‑stage, or not well controlled. Reviews warn that current results are promising but need larger, careful trials. 15091 15085 15058
  • People of color were underrepresented in psychedelic research up to 2017. This means we cannot assume study results apply equally across different ethnic or cultural groups. 15095
  • The growing psychedelic industry raises ethical and safety questions. Reviewers note it is not always clear how much benefit comes from the drug itself versus the therapeutic care around it, and commercial pressures add uncertainty. 15087 15085

Is the Requirement for First-Person Experience of Psychedelic Drugs a Justified Component of a Psychedelic Therapist’s Training?

Nathan Emmerich, Bryce Humphries

This paper looks at whether trainee psychedelic therapists should be required to take psychedelic drugs so they can understand patients' experiences. The authors review the idea that first-person psychedelic trips give special knowledge, and they argue this benefit is not clearly unique or proven. They conclude that forcing trainees to…

Chemical synthesis and alkaloids Diverse academic research themes Psychedelics and Drug Studies Ayahuasca Ketamine
Summaries and links are for general information and education only. They are not a substitute for reading the original publication or for professional medical, legal, or other advice. Always refer to the linked source for the full study.